290
Participants
Start Date
February 21, 2020
Primary Completion Date
April 7, 2027
Study Completion Date
April 7, 2027
Daratumumab
Participants will receive daratumumab.
Talquetamab
Participants will receive talquetamab.
Teclistamab
Participants will receive teclistamab.
Pomalidomide
Participants will receive pomalidomide.
The Blavatnik Family Chelsea Medical Center at Mount Sinai, New York
Mount Sinai Medical Center, New York
University of Pennsylvania, Philadelphia
Universitaetsklinikum Hamburg Eppendorf, Hamburg
Wake Forest Baptist Medical Center, Winston-Salem
Hosp Univ Fund Jimenez Diaz, Madrid
Levine Cancer Institute, Charlotte
Clinica Univ. de Navarra, Pamplona
Hosp Clinico Univ de Salamanca, Salamanca
Vanderbilt Ingram Cancer Center, Nashville
Medical College Of Wisconsin, Milwaukee
Universitaetsklinikum Heidelberg, Heidelberg
Universitatsklinikum Freiburg, Freiburg im Breisgau
City of Hope National Medical Center, Duarte
City of Hope Orange County Lennar Foundation Cancer Center, Irvine
University of California San Francisco, San Francisco
Universitatsklinikum Wurzburg, Würzburg
Arthur J E Child Comprehensive Cancer Centre, Calgary
University Health Network UHN Princess Margaret Cancer Centre, Toronto
VU Medisch Centrum, Amsterdam
LUMC, Leiden
Hosp Clinic de Barcelona, Barcelona
Inst. Cat. Doncologia-H Duran I Reynals, Barcelona
Germans Trias I Pujol, Barcelona
Janssen Research & Development, LLC
INDUSTRY